Document text
Principal Investigator: Sara Tartof
Organization: KAISER FOUNDATION RESEARCH INSTITUTE
Fiscal Year: 2024
Award: $760,514
Funding agency: National Institute of Allergy and Infectious Diseases
SUMMARY/ABSTRACT
In 2015, tuberculosis (TB) surpassed HIV as the number one cause of infectious disease deaths worldwide. In
the U.S., California has the highest incidence and largest number of TB cases in the nation, comprising nearly
one-quarter of all new active TB cases in 2017. More than 80% of active TB disease in the U.S. is due to
reactivation, which could be prevented via screening and treatment of LTBI. Yet, adoption of the latent TB
screening and treatment guidelines has been extremely poor. The screening guidelines are inefficient and rely
on data that are almost never available to clinicians, and the treatment guidelines are confusing. Further,
treatment initiation and completion rates are low for patients with LTBI and the barriers to successful treatment
are poorly understood. To address these missed opportunities, we will use expansive electronic health record
data across 2 of the largest healthcare institutions in California as well as qualitative data from LTBI
stakeholders to conduct three specific aims. For Aim 1, we will look at current gaps in screening practices for
LTBI, as well as gaps in the guidelines themselves, by simulating what it would look like if screening was being
perfectly implemented. To do this, we will collect laboratory testing data for LTBI stratified by characteristics of
interest and will use modeling to estimate the number of TB cases prevented by current screening as a
measure of effectiveness. We will use simulation models to estimate effectiveness of optimal screening. For
Aim 2, we will develop and validate new screening and treatment guidelines for LTBI based on variables widely
available in electronic health records. First, we will use machine learning and traditional regression to identify
risk factors for positive LTBI tests and reactivation TB. Next, we will assign risk scores to each risk factor, and
will use joint probability analyses to identify populations at greatest need for screening and treatment. To
estimate performance of the newly proposed strategy, we will use simulation modeling. For Aim 3, we will
develop and pilot a culturally-tailored educational video intervention to improve LTBI treatment initiation and
completion. We will first identify barriers to treatment adherence through qualitative interviews with patients
and providers and will subsequently develop a short video based on findings from the interview. We will
perform an individually randomized efficacy trial to assess impact of the intervention on initiation and treatment
completion rates. The approach is innovative because we propose a complete re-framing of the current U.S.
LTBI control strategy in a way that dramatically enhances ease-of-use for frontline providers. Results of this
work will make a significant contribution to public health by providing low-cost and easily expandable solutions
to address ongoing and substantial gaps in the current LTBI care continuum.
Terms: <AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Adoption><California><Caring><Cessation of life><Characteristics><Collaborations><Communicable Diseases><Confusion><Confusional State><Continuity of Care><Continuity of Patient Care><Continuum of Care><Data><Death><Disease><Disorder><EHR system><Education><Education for Intervention><Educational Intervention><Educational aspects><Effectiveness><Electronic Health Record><Guidelines><HIV><Healthcare><History><Human Immunodeficiency Viruses><Incidence><Individual><Infection Control><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Institution><Instruction Intervention><Intervention><Intervention Strategies><Interview><Joints><Knowledge><LAV-HTLV-III><Laboratories><Lymphadenopathy-Associated Virus><M tuberculosis infection><M. tb infection><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MTB infection><Machine Learning><Medical><Mental Confusion><Modeling><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><Patient Care><Patient Care Delivery><Patients><Performance><Persons><Pharmacies><Pharmacy facility><Population><Population Heterogeneity><Position><Positioning Attribute><Probability><Provider><Public Health><Randomized><Recording of previous events><Research><Research Resources><Resources><Risk><Risk Factors><TB infection><Testing><Time><Training Intervention><Translating><Tuberculosis><United States><Virus-HIV><Work><Writing><assess effectiveness><barrier to care><barrier to health care><barrier to healthcare><barrier to treatment><care for patients><care of patients><caring for patients><clinical practice><compare effectiveness><cost><culturally adapted intervention><culturally appropriate intervention><culturally centered intervention><culturally focused intervention><culturally informed intervention><culturally responsive intervention><culturally tailored intervention><data resource><design><designing><determine effectiveness><disseminated TB><disseminated tuberculosis><diverse populations><effectiveness assessment><effectiveness evaluation><effectiveness measure><efficacy trial><electronic health care record><electronic health medical record><electronic health plan record><electronic health record system><electronic health registry><electronic medical health record><ethnic diversity><ethnically diverse><evaluate effectiveness><evidence base><examine effectiveness><experience><health care><health care organization><health care service organization><healthcare organization><healthcare service organization><heterogeneous population><histories><improved><infection due to Mycobacterium tuberculosis><innovate><innovation><innovative><instructional intervention><interest><interventional strategy><machine based learning><member><model-based simulation><models and simulation><new approaches><novel approaches><novel strategies><novel strategy><obstacle to care><obstacle to healthcare><point of care><population diversity><prevent><preventing><racial diversity><racially diverse><randomisation><randomization><randomly assigned><recommended screening><screening><screening guidelines><screening program><screening recommendations><screenings><simulation><therapeutic stratification><treatment adherence><treatment compliance><treatment guidelines><treatment stratification><tuberculosis infection><tuberculous spondyloarthropathy><wasting>